Early research (Phase 1)Study completedNCT03316521
What this trial is testing
First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers
Who this might be right for
Complement Mediated Diseases
Amyndas Pharmaceuticals S.A. 50